CAS 81624-55-7
:N,N,N',N'-tétrakis[(6-méthyl-1H-benzimidazol-2-yl)méthyl]éthane-1,2-diamine
- Tri par prix ascendant
- Tri par prix descendant
- Puretés inférieures
- Puretés supérieures
- Livraison estimée la plus rapide
NSC348884
CAS :Formule :C38H40N10Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :636.7912NSC348884
CAS :NSC348884, a nucleophosmin inhibitor, disrupts oligomers, induces apoptosis, and inhibits cancer cell growth (IC50: 1.7-4.0 μM).Formule :C38H40N10Degré de pureté :98.69% - 99.91%Couleur et forme :SolidMasse moléculaire :636.7912NSC348884
CAS :N1,N1,N2,N2-Tetrakis((6-methyl-1H-benzo[d]imidazol-2-yl)methyl)ethane-1,2-diamineFormule :C38H40N10Degré de pureté :99%Masse moléculaire :636.79N1,N1,N2,N2-Tetrakis((6-methyl-1H-benzo[d]imidazol-2-yl)methyl)ethane-1,2-diamine
CAS :Degré de pureté :99%Masse moléculaire :636.8079834Ref: 10-F869984
1gÀ demander10mgÀ demander25mgÀ demander50mgÀ demander100mgÀ demander250mgÀ demander5mg35,00€NSC348884
CAS :NSC348884 is a novel anti-cancer drug that is an inhibitor of RNA polymerase. It has been shown to inhibit cellular transformation and viability in human leukemia HL-60 cells and prostate cancer cells, as well as inducing apoptosis. The mechanism of action of NSC348884 may be mediated through the induction of reactive oxygen species (ROS), activation of caspases, and modulation of signal transduction pathways. NSC348884 has also been shown to induce a variety of transcriptional effects on tumor cells, including upregulation or downregulation of genes involved in cell cycle regulation and apoptosis. This drug is also efficacious against brain tumors with malignant characteristics and breast cancer cells that are resistant to monoclonal antibody therapy.
Formule :C38H40N10Degré de pureté :Min. 95%Masse moléculaire :636.79 g/mol






